Leopold Bertea

Chief Technology Officer at Mendus AB

Speaker

Leopold BERTEA, Ph.D., is Chief Technology Officer of Mendus since May 2022, driving the build-up of a global manufacturing infrastructure for the company’s lead program, vididencel (Phase II), leading all technical development and CMC activities, ilixadencel (Phase II) and the NK cell program based on dendritic cell biology. Dr.Bertea joined Mendus from Cellectis, where he was SVP Technical Operations Europe. With previous senior roles at Novartis, LFB Biotechnologies, LFB’s subsidiary CELLforCURE, and Sanofi, Dr. Bertea cumulates 30 years biopharmaceutical industry experience, in process development, manufacturing of complex biologics including combination products, and cell & gene therapies both allogeneic and autologous. He covered senior roles managing clinical and commercial manufacturing sites, global R&D teams, as well as negotiating and managing collaborations in several countries. Dr.Bertea holds a Ph.D. in Chemical Engineering from ETH Zurich.